latest news releases from the newsroom
Wall Street Transcript Interviews NaturalNano, Inc. Acting President and CEO, James Wemett
ROCHESTER, N.Y., May 14, 2009 (GLOBE NEWSWIRE) -- NaturalNano, Inc. (OTCBB:NNAN) (Frankfurt:N3N), a developer of extended release technologies and supplier of polymer additives based on naturally occurring nanomaterials, is featured in an interview by Wall Street Transcript. The interview will appear in the May 18th issue. Commenting on the interview, Mr. Wemett, said, "We are pleased that The Wall Street Transcript has chosen to feature NaturalNano in its May 18th issue and on their website. This increased attention being paid to NaturalNano's controlled release HNT technology, Halloysite Natural Tubular products and their market potential plus our extensive patent portfolio is exciting."
Deal Volume Tumbles At the Start of 2009 in the Global Transportation & Logistics, Industrial Manufacturing, Metals, and Chemicals Industries, Finds PricewaterhouseCoopers
NEW YORK, May 14, 2009 (GLOBE NEWSWIRE) -- The pace of mergers and acquisitions drastically declined across industrial products sectors, according to a series of first-quarter M&A reports released today by PricewaterhouseCoopers LLP (PwC). Deal volume in the global transportation and logistics (T&L), industrial manufacturing, metals, and chemicals industries came to a near halt in first quarter 2009 as economic uncertainties continued to loom across the globe.
DARA BioSciences, Inc.
DARA BioSciences to Present DB959 At the 'Annual Targeting Diabetes with Novel Therapeutics' Meeting Sponsored by Cambridge Healthtech Institute
RALEIGH, N.C., May 14, 2009 (GLOBE NEWSWIRE) -- Today DARA BioSciences, Inc. (Nasdaq:DARA) announced that the DB959 program has been identified by Cambridge Healthtech Institute ("CHI") for inclusion in its 2nd Annual 'Targeting Diabetes with Novel Therapeutics' meeting. Mary Kay Delmedico, Ph.D., will present a 25 minute talk entitled "DB959: A Novel, Dual PPAR delta/gamma Agonist (DB959) for the Treatment of Type 2 Diabetes" as part of the multi-track Discovery on Target ("DOT") Conference being held in Boston, MA, November 3-4, 2009. Additional information about the conference can be found at http://www.discoveryontarget.com.